Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood by Ramakrishnan, Lakshmy et al.
RESEARCH Open Access
Relationship of APOA5, PPARg and HL gene
variants with serial changes in childhood body
mass index and coronary artery disease risk
factors in young adulthood
Lakshmy Ramakrishnan
1*, Harshpal S Sachdev
2, Meenakshi Sharma
3, Ransi Abraham
1, Swami Prakash
4,
Dileep Gupta
2, Yogendra Singh
1, Seema Bhaskar
4, Shikha Sinha
2, Giriraj R Chandak
4, Kolli S Reddy
5 and
Bhargava Santosh
6
Abstract
Background: Triglycerides is an independent risk factor for coronary artery disease (CAD) and is especially
important in Indians because of high prevalence of hypertriglyceridemia in this population. Both genetic and
environmental factors determine triglyceride levels. In a birth cohort from India, hypertriglyceridemia was found in
41% of men and 11% of women. Subjects who had high triglycerides had more rapid body mass index (BMI) or
weight gain than rest of the cohort throughout infancy, childhood and adolescence. We analysed polymorphisms
in APOA5, hepatic lipase and PPARg genes and investigated their association with birth weight and serial changes
in BMI.
Results: Polymorphisms in APOA5 (-1131T > C, S19W), PPARg (Pro12Ala) and hepatic lipase (-514C > T) were
studied by polymerase chain reaction (PCR) followed by restriction digestion in 1492 subjects from the New Delhi
Birth Cohort (NDBC). We assessed whether these polymorphisms influence lipid and other variables and serial
changes in BMI, both individually and together.
The risk allele of APOA5 (-1131C) resulted in 23.6 mg/dl higher triglycerides as compared to normal allele (P <
0.001). Risk allele of HL (-514T) was associated with significantly higher HDL2 levels (P = 0.002). Except for the
marginal association of PPARg Pro12Ala variation with a lower conditional weight at 6 months, (P = 0.020) and
APOA5 S19W with a higher conditional BMI at 11 yrs of age (P = 0.030), none of the other associations between
the gene polymorphisms and serial changes in body mass index from birth to young adulthood were significant.
Conclusion: The promoter polymorphism in APOA5 was associated with raised serum triglycerides and that of HL
with raised HDL2 levels. None of the polymorphisms had any significant relationship with birth weight or serial
changes in anthropometry from birth to adulthood in this cohort.
Background
Interaction between genetic and environmental factors
determines susceptibility of an individual to develop cor-
onary artery disease. Triglyceride is an independent risk
factor for coronary artery disease (CAD) and is espe-
cially important in Indians because of high prevalence of
hypertriglyceridemia in this population. In a well-estab-
lished birth cohort (New Delhi Birth Cohort, NDBC) of
individuals born between the years 1969 to 1973 and
followed up in many phases in terms of anthropometric
measures and in 2002 for biochemical risk factors of
diabetes and CVD, we have earlier demonstrated an
inverse relation between thinness in infancy and the
presence of impaired glucose tolerance or diabetes in
1492 young adults [1]. The New Delhi Birth Cohort was
drawn from all families living in a defined are of South
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119,799 there were 20,755 married women of reproduc-
tive age who were assessed every other month in order
to record menstrual dates. Women who became preg-
nant were visited every two months initially and alter-
nate days from 37
th week of gestation. There were 9169
pregnancies resulting in 8181 live births. Trained per-
sonnel recorded the weight and the length of the babies
within 72 hrs of birth, at the ages of 3, 6, 9 and 12
months (±7 days) and at 6 months interval thereafter.
There were many phases in this cohort study (phase 1:
1969-1973, phase 2: 1974-1980, phase 3: 1983-1987,
phase 4: 1987-1991, Current phase: 1998-2002). More
than 30% of the cohort was lost between the end of
phase I and beginning phase 2, a time when unauthor-
ized housing was demolished in South Delhi. In the cur-
rent phase, between 1998-2002, 31.6% of the initial
cohort could be located. 1526 subjects provided consent
and participated. Close to 1/10
th of these subjects had
impaired glucose tolerance (10.8%), and 4.4% were dia-
betic. Another important finding was that 41% of men
and 11% of women had hyper-triglyceridemia. Subjects
who had high triglycerides had more rapid body mass
index (BMI) or weight gain than rest of the cohort
throughout infancy, childhood and adolescence [2].
Triglyceride metabolism is both under genetic and
environmental influences. It is likely that genes which
influence triglyceride levels have different effects on peo-
ple with different birth weight and or weight at infancy
or childhood [3]. APOA5 is an important determinant of
triglyceride levels [4] and it’s over expression results in
decreased plasma triglyceride levels [5]. Two polymorph-
isms, -1131T > C and S19W, in the APOA5 gene have
been shown to be associated with raised triglyceride
levels in different populations [4]. PPAR-g regulates a
number of adipocyte genes involved in pathways of lipid
metabolism. A “G” to “C” substitution in exon coding for
PPAR-g results in proline to alanine amino acid change
(PPARg Pro12Ala). The Ala isoform of PPAR-g is less
effective at targeting genes and is found to be signifi-
cantly associated with dyslipidemia in obese [6]. Hepatic
lipase hydrolyzes triglycerides from lipoproteins in circu-
lation. Polymorphism in promoter region in the HL gene
(C-514T) is associated with diminished lipase activity,
dyslipidemia, and atherosclerosis [7]. We studied the
relative role of two APOA5 gene polymorphisms: -1131T
>Ca n dS 1 9 W ,PPARg gene polymorphism- Pro12Ala
and hepatic lipase C-514T polymorphism on lipid levels
and also the relationship with serial changes in BMI from
birth to adulthood in the NDBC.
Subjects and methods
The study was carried out from blood samples of the
NDBC subjects (n = 1492) stored at -70°C which were
collected during the period 1998 to 2002 (Details pub-
lished elsewhere [1]). Demographic details available for
the subjects included sex, age, residence, socio-economic
status, education and employment. Anthropometric
measurements including birth weight, length and gesta-
tion, serial anthropometric profile from birth till young
adulthood (six monthly intervals), and current weight,
height, waist, and hip circumferences, skin fold thick-
nesses (triceps and subscapular) were also available. The
methods of estimations have been detailed in the earlier
publication [1]. Fresh blood samples were collected for
measurement of LDL particle diameter and HDL3 levels.
LDL particle diameter was measured by electrophoresis
[8]. HDL 3 was measured in serum by dual precipitation
method [9]. HDL2 was derived from total HDL and
HDL3. The study was approved by the All India Insti-
tute of Medical Sciences (AIIMS) research ethics com-
mittee and informed consent was taken from all
subjects.
DNA extraction and genotyping
DNA was extracted by salting out method [10]. APOA5
-1131T > C polymorphism was genotyped by ARMS
(Amplification Refractory Mutation System)-PCR
method described by Chandak et al [11]. The primers
amplify a control product of 404 bp while the PCR pro-
ducts of 250 bp and 242 bp identify T and C alleles
respectively. The S19W polymorphism in APOA5 was
determined by PCR-RFLP amplifying a 157 bp product.
To determine PPAR-g Pro12Ala polymorphism, muta-
genically separated PCR was performed. A 230 bp pro-
duct identifies the Pro allele and 250 bp product the Ala
allele. To assay the C-514T HL polymorphism in the
promoter region, a 299-bp fragment containing the
restriction site was PCR-amplified. The amplified DNA
was digested with Nla III generating two fragments of
229 bp and 70 bp in subjects with “T” allele. Positive
and negative controls were included in all RFLP runs.
For quality assurance of data generated, 10% samples
were regenotyped at CCMB and a near 100% concor-
dance was observed. This validates the data generated
on all the samples and hence the association analyses
conducted on the genotypic and allelic frequency is
robust
Statistical methods
All biochemical parameters were analyzed for normality.
Appropriate transformations were required for skewed
variables prior to analyses. Allele frequencies were com-
puted by allele counting. Concordance of genotype fre-
quencies with Hardy Weinberg equilibrium (HWE) was
tested with c2 goodness of fit. We investigated the rela-
tionship between genotype and all biochemical and clin-
ical variables by ANOVA and the linear differences in
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associations were also tested with the dominant and
recessive models. We generated weight, height and BMI
internal sex-specific standard deviation (SD) scores. We
modeled the progress of the median, spread and skew-
ness of the measurements as age increased. For each
subject we interpolated values linearly between succes-
sive SD scores to estimate SD scores at 6 months and at
birthdays from 1 to 21 years. The interpolated values
were used if measurements were made within 6 months
(up to 1 year), 1 year (age 2 years), 1.5 years (age 3
years) and 2 years (all older ages). Back-transformation
provided estimates of measurements at these ages. In
order to measure changes in early-life BMI and height
(growth), we used the conditional SD scores method.
We divided growth into three periods: birth to 2 years
(infancy), 2-11 years (pre-pubertal childhood growth)
and 11 years to adulthood (adolescent growth). To
describe growth during each interval, for example
between 2 and 11 years, we regressed SD scores at the
end of the interval (11 years) on SD scores at the begin-
ning (2 years) and at all preceding time points (birth, 6
months, 1 year), and expressed the residuals as SD
scores. This produces uncorrelated variables describing
change between specific ages (conditional SD scores).
We also conducted multiple linear regression analyses
for evaluating the associations after adjustment for
confounders.
Results
C and S19W in APOA5, C-514T in hepatic lipase and
Pro12Ala in PPAR-γ polymorphisms in the NDBC
cohort",1,0,1,0,0pc,0pc,0pc,0pc>Frequency of -1131T >
C and S19W in APOA5, C-514T in hepatic lipase and
Pro12Ala in PPAR-g polymorphisms in the NDBC cohort
The allelic and genotype frequencies of the four evalu-
ated SNPs are depicted in Table 1. The risk allele fre-
quency of hepatic lipase (C-514T) was highest (22.9%),
then APOA5 (-1131T > C) (18.7%), followed by PPAR-g
(Pro 12Ala) (11.2%). APOA5 (S19W) minor allele was
rare (4.0%). The genotype frequencies at all the poly-
morphisms did not deviate from the Hardy-Weinberg
equilibrium (p > 0.05).
Inter-relationship between gene variants and coronary
artery disease risk factors in adults
The inter-relationship between the four polymorphisms
and lipid variables for both sexes combined is depicted
in Table 2. The analyses were also performed for men
and women separately (data not given).
A significant difference in triglycerides was evident
with subjects having “CC” genotype showing the highest
mean triglyceride levels (p < 0.0001 for linear trend).
This association remained significant when males (p <
0.001) and females (p = 0.046) were analyzed separately.
The age, sex and BMI adjusted effect size per allele of
the linear association between APOA5 (-1131T > C)
SNP and serum triglyceride level was considerable (23.6
mg/dl, 95% CI 16.0 to 31.2). Serum cholesterol was also
significantly higher in subjects with CC genotype (p =
0.007 for linear trend). Associations with other lipid
variables were not significant. In view of the low minor
allele frequency (MAF) of APOA5 S19W, a combined
analysis of heterozygous (SW) and homozygous subjects
for W allele (WW) was considered to be more pertinent.
Although triglyceride concentration tended to be higher
and HDL concentration lower in subjects with minor
allele, the differences were not statistically significant by
recessive model (p = 0.069 and p = 0.461, respectively).
No consistent significant associations were observed
between APOA5 (S19W) polymorphism and any of the
other evaluated outcome measures.
For HL (C-514T), HDL2 was higher in subjects with
the minor allele (p = 0.002 by linear trend and p < 0.0001
by recessive model). This association remained significant
in males when analyzed separately whereas it was weaker
in females (p = 0.011). The significant association
between C-514T variation in hepatic lipase and HDL2
subfraction persisted even after adjustment for age, gen-
der and BMI (p = 0.002). There was a significant
Table 1 Frequency (%) of single nucleotide polymorphisms (SNP) in Subjects
SNP N Wild Homozygous
N (%)
Heterozygous
N (%)
Mutant Homozygous
N (%)
Minor Allele
frequency
P value*
Hepatic lipase
(-514C > T)
1326 797 (60.1) 451 (34.0) 78 (5.9) 22.9 0.414
PPAR-g
(Pro12Ala)
rs1801282
1219 970 (79.6) 231 (18.9) 18 (1.5) 11.0 0.611
APOA5
(-1131T > C)
rs662799
1226 811 (66.2) 372 (30.3) 43 (3.5) 18.7 0.999
APOA5
(S19W) rs3135506
1140 1053 (92.4) 84 (7.4) 3 (0.3) 4.0 0.633
* P value for Hardy-Weinberg equilibrium
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Page 3 of 8Table 2 Association of APOA5 (-1131T > C, S19W), HL (C-514T) and PPAR g (Pro12Ala) genotypes with lipid variables in
adults
Genotype (n) Cholesterol
(mg/dl)
Triglycerides
(mg/dl)
Total HDL
(mg/dl)
HDL2
(mg/dl)
*
LDL
(mg/dl)
LDL particle size
(nm)
APOA5 (-1131T > C)
TT (779) 191.5 ± 41.3 126.9 ± 70.1 47.5 ± 11.4 17.0
(13.0-21.0)
118.4 ± 34.8 27.0 ± 0.6
TC (350) 196.9 ± 41.9 150.5 ± 96.7 46.1 ± 11.7 17.0
(13.0-21.0)
119.6 ± 34.8 26.9 ± 0.6
CC (41) 205.2 ± 43.2 184.4 ± 104.1 46.0 ± 10.5 18.0
(13.5-22.5)
122.3 ± 34.4 27.0 ± 0.6
P value 0.025 <0.0001 0.132 0.822 0.703 0.760
P value (linear trend) 0.007 <0.0001 0.055 0.558 0.418 0.550
Deviation from linearity 0.714 0.505 0.542 0.827 0.823 0.661
P value (Dominant Model)
(1129/41)
0.068 <0.0001 0.562 0.619 0.522 0.978
P value (Recessive Model)
(779/391)
0.015 <0.0001 0.044 0.624 0.487 0.480
APOA5 (S19W)
SS (1000) 192.3 ± 41.7 133.2 ± 80.2 46.9 ± 11.5 17.0
(13.0-21.0)
118.5 ± 35.1 27.0 ± 0.6
SW/WW (84) 197.1 ± 41.2 149.9 ± 89.8 45.9 ± 13.1 18.0
(14.0-20.75)
120.7 ± 33.6 26.9 ± 0.7
P value (Dominant Model)
(1081/3)
0.324 0.030 0.016 0.928 0.542 0.417
P value (Recessive Model)
(1000/84)
0.312 0.069 0.461 0.742 0.578 0.491
HL (C-514T)
CC (756) 191.8 ± 40.0 133.7 ± 80.8 47.1 ± 11.6 17.0
(12.0-20.0)
117.6 ± 33.4 27.0 ± 0.6
CT(434) 194.7 ± 43.4 134.6 ± 78.8 47.6 ± 11.7 18.0
(14.0-23.0)
119.7 ± 36.4 27.0 ± 0.6
TT(76) 196.6 ± 48.6 159.6 ± 100.0 46.3 ± 12.3 18.0
(13.0-23.0)
118.2 ± 38.6 26.9 ± 0.5
P value 0.404 0.029 0.591 0.002 0.604 0.090
P value (linear trend) 0.180 0.065 0.960 0.002 0.460 0.921
Deviation from linearity 0.893 0.056 0.306 0.098 0.496 0.028
P value (Dominant Model)
(1190/76)
0.451 0.008 0.450 0.451 0.958 0.106
P value (Recessive Model)
(756/510)
0.196 0.318 0.669 <0.0001 0.348 0.367
PPARg (Pro12Ala)
Pro12Pro (916) 193.0 ± 41.6 136.2 ± 82.4 47.1 ± 11.8 17.0
(13.0-21.0)
118.1 ± 34.2 27.0 ± 0.7
Pro12Ala/Ala12Ala (245) 195.4 ± 44.3 138.7 ± 80.7 47.7 ± 11.4 17.0
(14.0-21.75)
119.8 ± 38.7 27.0 ± 0.6
P value (Dominant Model)
(1143/18)
0.136 0.029 0.820 0.110 0.415 0.493
P value (Recessive Model)
(916/245)
0.437 0.671 0.473 0.173 0.496 0.530
Values are mean ± SD
* Transformed (square root) values were used.
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0.029 and p = 0.008 dominant model). No consistent sig-
nificant associations were observed between polymorph-
ism at PPAR-g (Pro 12Ala) and any of the evaluated
outcome measures. The significant association with
serum triglyceride in dominant model (p = 0.029) was
not evident in recessive model (p = 0.671).
There was no significant association with any of the
four polymorphisms and the presence of hypertension
(except for PPAR-g) and impaired glucose tolerance or
diabetes (Table 3). A borderline statistically significant
association was documented between the PPAR-g (Pro
12Ala) SNP and hypertension (p = 0.042).
Inter-relationship between gene variants and serial
changes in body mass index and weight from birth to
young adulthood
Participants had a mean (SD) of 23 (5.5) observations
between birth and the age of 21 years. Association
between BMI at birth and conditional BMI at later ages
and gene variants is given in Table 4. Associations
between birth weight and conditional weight at later
ages were also analyzed (data not shown). In view of
sample size restrictions, the recessive model may be a
more meaningful assessment of the relationship. With
the recessive model, except for two, none of the other
associations between the gene polymorphisms and serial
changes in body mass index or weight from birth to
young adulthood were statistically significant. PPAR
gamma Pro12Ala variation was associated with a lower
conditional weight (p = 0.020) at 6 months (data not
shown) and APOA5 S19W with a higher conditional
BMI at 11 yrs (p = 0.030), With the dominant model,
except for three, no other associations were significant.
The APOA5 (-1131T > C) minor allele was significantly
associated with a higher BMI at birth (p = 0.001) and
lower conditional BMI at 2 years (p = 0.05). HL (C-
514T) minor allele was significantly associated with
lower conditional BMI at 2 years (p = 0.034).
C and hepatic lipase C-514T for serum
triglyceride",1,0,1,0,0pc,0pc,0pc,0pc>Interaction between
APOA5 -1131T > C and hepatic lipase C-514T for serum
triglyceride
Amongst 1169 participants, 153 (13.1%) subjects had a
minor allele of both APOA5 -1131T > C and HL C-
514T. There was evidence of a significant negative (p =
0.022) interaction between -1131T > C polymorphism in
APOA5 and C-514T polymorphism in hepatic lipase for
their age, sex and BMI adjusted association with serum
triglyceride levels (Table 5). In the presence of a normal
allele of APOA5 or hepatic lipase, the presence of minor
Table 3 Prevalence of IGT/Diabetes and Hypertension in relation to genotype
SNP IGT/Diabetes present %(n) P value Hypertension present %(n) P value
APOA5 (-1131T >C)
(Dominant Model)
TT & TC 15.2 (1093) 0.168 9.6 (1132) 0.387
CC 22.0 (41) 11.9 (42)
APOA5 (-1131T >C)
(Recessive Model)
TT 14.9 (753) 0.258 10.4 (778) 0.151
TC &CC 16.5(381) 8.3 (396)
APOA5 (S19W)
(Dominant Model)
SS & SW 15.3 (1044) 0.717 8.9 (1087) 0.246
WW 0.0 (2) 33.3 (3)
APOA5 (S19W)
(Recessive Model)
SS 15.6 (967) 0.203 8.8 (1008) 0.312
SW&WW 11.4 (79) 11.0 (82)
HL (C-514T)
(Dominant Model)
CC & CT 15.6 (1151) 0.233 9.8 (1192) 0.480
TT 19.4 (72) 10.5 (76)
HL (C-514T)
(Recessive Model)
CC 14.3 (732) 0.055 9.5 (761) 0.313
CT&TT 17.9 (491) 10.5 (507)
PPARg (Pro12Ala)
(Dominant Model)
Pro12Pro & Pro12Ala 15.5 (1104) 0.546 9.6 (1148) 0.476
Ala12Ala 16.7 (18) 5.6 (18)
PPARg (Pro12Ala)
(Recessive Model)
Pro12Pro 15.2 (884) 0.297 8.7 (921) 0.042
Pro12Ala & Ala12Ala 16.8 (238) 12.7 (245)
Ramakrishnan et al. Lipids in Health and Disease 2011, 10:68
http://www.lipidworld.com/content/10/1/68
Page 5 of 8allele in the other gene was associated with a significant
elevation in serum triglyceride level (10.5 mg/dl for
h e p a t i cl i p a s ea n d2 9m g / d lf o rAPOA5). However, the
combination of a minor allele of APOA5 or hepatic
lipase with the minor allele of the other gene (hepatic
lipase or APOA5) was associated with a decline (not sta-
tistically significant) in serum triglyceride level (Table
5). Thus while considering both the mutations simulta-
neously, as the genotype shifts from wild type to risk
one, the association becomes negative.
Discussion
To the best of our knowledge no study has evaluated
the relationship of polymorphisms in APOA5,h e p a t i c
lipase and PPARg and serial changes in body mass index
from birth to adulthood. In our study, APOA5 1131T >
C minor allele was associated with significantly higher
triglycerides and that of HL C-514T was associated with
higher HDL2. PPAR gamma Pro12Ala variation was
associated with a lower conditional weight at 6 months
in heterozygous subjects and those homozygous for
minor allele. APOA5 S19W was associated with a higher
conditional BMI at 11 yrs in heterozygous subjects and
those homozygous for minor allele. None of the other
associations between the gene polymorphisms and serial
changes in body mass index or weight from birth to
young adulthood were statistically significant.
The minor allele frequency of APOA5 -1131T > C was
more prevalent than the S19W polymorphism in the
NDBC (18.7% vs. 4%, respectively). Chandak et al [11]
reported a comparable frequency of less common allele
of -1131T > C polymorphism in the promoter region of
APOA5 in 20% and that of S19W in 3% in Pune Indians
whereas the allele frequency for both SNPs in UK white
subjects were 4% and 6%. The reported prevalence of
-1131C allele from other parts of the world varies
between 6.4% in American Caucasian males [12] and
Table 4 Inter-relationship between polymorphisms at -1131T >C of APOA5, S19W of APOA5, C-514T of Hepatic lipase
and Pro12Ala of PPARg with BMI at birth and conditional BMI at 6 months, 2 yrs, 11 yrs and adulthood
Conditional BMI
(n)
at birth
Mean ± SD
6 months
Mean ± SD
2 Yrs
Mean ± SD
11Yrs
Mean ± SD
Adult
Mean ± SD
APOA5 -1131T > C
TT 0.006 ± 0.99 -0.008 ± 0.96 0.007 ± 0.97 -0.019 ± 0.99 0.036 ± 0.96
TC/CC 0.024 ± 1.03 -0.014 ± 1.02 -0.011 ± 0.99 0.053 ± 1.02 -0.003 ± 1.04
P value (Dominant Model) (846/34) 0.001 0.830 0.050 0.242 0.697
P value (Recessive Model) (592/288) 0.803 0.935 0.802 0.312 0.578
APOA5 S19W
SS 0.039 ± 1.00 0.003 ± 0.98 0.014 ± 1.00 -0.019 ± 0.98 0.012 ± 0.99
SW/WW -0.071 ± 0.92 0.146 ± 0.96 0.003 ± 1.02 0.261 ± 1.01 -0.038 ± 1.05
P value (Dominant Model) (833/2) 0.848 0.185 0.835 0.551 0.173
P value (Recessive Model) (772/63) 0.397 0.270 0.937 0.030 0.700
HL (C-514T)
CC -0.004 ± 1.02 -0.031 ± 1.00 0.020 ± 1.01 -0.043 ± 0.98 0.032 ± 1.01
CT/TT 0.030 ± 0.98 0.004 ± 1.01 -0.050 ± 1.00 0.036 ± 1.00 0.002 ± 0.96
P value (Dominant Model) (897/59) 0.854 0.229 0.034 0.751 0.821
P value (Recessive Model) (581/375) 0.610 0.598 0.295 0.225 0.645
PPARg (Pro12Ala)
Pro12Pro (730) -0.014 ± 0.98 0.004 ± 1.00 0.025 ± 0.98 -0.002 ± 1.00 0.018 ± 0.97
Pro12Ala/Ala12Ala (186) 0.058 ± 1.10 -0.151 ± 0.94 -0.074 ± 1.04 -0.026 ± 0.99 0.033 ± 1.05
P value (Dominant Model) (863/14) 0.991 0.164 0.108 0.791 0.945
P value (Recessive Model) (703/174) 0.394 0.065 0.241 0.782 0.853
Table 5 Age, Sex and BMI adjusted interaction between
hepatic lipase and APOA5 and triglyceride levels
Serum triglycerides
Model B 95% CI P
Constant 112.74 -69.35, 294.82 0.225
Adult age (yrs) -2.47 -7.32, -2.39 0.318
Sex -51.92 -62.39, -41.45 0.000
BMI 2.21 1.16, 3.27 0.000
APOA5 -1131T > C 56.47 23.88, 89.07 0.001
HL C-514T 40.31 8.95, 71.67 0.012
APOA5/HL -25.91 -48.00, -3.82 0.022
Dependent Variable: Serum triglyceride (mg/dl)
APOA5/HL represents the interaction term between APOA5 -1131T > C and C-
514T Hepatic Lipase.
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allele frequency varies between 0.1% in a Chinese popu-
lation [14] and 15.8% in Hispanic males [11].
We observed that the presence of the -1131C allele
was associated with 23.6 mg/dl higher fasting triglycer-
ide concentrations and 9.9 mg/dl higher post-prandial
triglycerides. The reported effect size on triglyceride
concentration of the less common “C” allele varies from
about 30% in Caucasians [15] to 36% in Chinese [16]
and 60% in Turks [17].
We observed a minor allele frequency of 22.9% for C-
514T polymorphism in hepatic lipase. The minor allele
frequency of 0.15-0.21 has been reported among Cauca-
sians, 0.45-0.53 among Africans and 0.47 among Japa-
nese suggesting considerable ethnic differences.
However, a meta-analysis of 25 studies involving nearly
25,000 subjects reported an overall T allele frequency of
25.3% [18]. Plasma HDL and cholesterol differed signifi-
cantly among genotypes, while LDL and triglycerides
levels were similar. To the best of our knowledge there
have been no studies on hepatic lipase polymorphisms
and their effect on lipids in Indians. We found a signifi-
cant increase in total HDL and HDL2 levels but not
HDL3 levels in carriers of T allele which is on similar
lines as reported previously [19-22]. HL is responsible
for the conversion of large HDL2 to smaller HDL3 par-
ticles by modulating phospholipids content of these par-
ticles. A lower HL activity in T carriers will therefore
result in higher levels of HDL2. There was a weak asso-
ciation between presence of T allele and triglycerides
with the carriers showing a trend towards higher trigly-
cerides in the present study, which is similar to the
results obtained in the meta-analysis [18].
Since the only significant effect we found were that of
APOA5 and hepatic lipase on triglycerides and HDL2
sub-fraction, we investigated the interaction between
these SNPs in determining triglyceride levels. It was
interesting to note the attenuation of the effect of
APOA5 variant on triglycerides in the presence of poly-
morphism in hepatic lipase and vice versa. Mutation in
either of the gene in the presence of a normal genotype
in the other gene was associated with higher triglycer-
ides as compared to mutation in both the genes. We
could not assess the dietary fat intake, which may inter-
act with HL and APOA5 polymorphisms to determine
APOA5 and HL activity.
We did not find any interaction between birth weight
or early growth and the analyzed polymorphisms in
determining lipid levels in later life. Ruiz et al [6] stu-
died the influence of APOE, APOC3 and PPARg2 gene
polymorphisms on lipid levels in people with low birth
weight. Low birth weight was associated with higher
total cholesterol, LDL cholesterol, and apoB/apoA in
males with APOE ε3 ε4 genotype whereas in males the
genotype was associated with lower HDL and higher tri-
glycerides. There were no associations between low
birth weight and blood lipids in any PPAR-g2 genotypes.
Effect of APOE genotype on total cholesterol, LDL and
ApoB has also been reported by others in children with
low birth weight [23,24]. The authors suggested that
c h a n g e si nA p o Eg e n ee x p r e s s i o nm a yb ep r o g r a m m e d
by in utero nutritional events. No group has examined
influence of APOA5 polymorphism on association
between birth weight and blood lipids till date. We
failed to find any interaction between APOA5 and birth
weight on lipids in our study. Limitation of the NDBC
study is that we have not captured current dietary intake
and current physical activity which may have an impor-
tant bearing on lipid levels.
We did not find any significant interaction between
birth weight and PPAR-g Pro12Ala genotype on lipid
levels. Data on interaction of birth weight and PPAR
gamma in determining lipids has been inconclusive with
one group underlying the influence of PPAR-g genotypes
on the association between birth weight and lipid levels
among elderly people [25] and others not finding any
significant interaction of birth weight on effect of PPAR-
g2 genotype on lipids [3,26]. These associations have
been linked to developmental plasticity whereby one
genotype can give rise to different phenotypes depend-
ing on conditions during development.
In conclusion, our study shows that polymorphism in
APOA5, PPAR-g and HL do not have any significant
relationship with the birth weight and serial changes in
anthropometry from birth to adulthood. The promoter
polymorphism in APOA5 is associated with a raised
serum triglyceride levels; the age, gender and BMI
adjusted effect size being substantial. The promoter
polymorphism in hepatic lipase is associated with higher
HDL2 levels. An interaction between polymorphisms in
APOA5 and hepatic lipase seems to influence the serum
triglyceride levels which need to be further explored.
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